Companies · Biotechnology

Hera Testing Laboratories, Inc.

LEXINGTON · Biotechnology

Diligence memoA one-page analyst read on Hera Testing Laboratories, Inc. — recommendation, valuation, rhythm, risks.
$3.4M
Total raised · real
4
Rounds
2.0×
Latest step-up
Top 65%
Sector rank · raised
Seed
Latest stage · inferred · Thu Jul 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Hera Testing Laboratories, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.71× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.
  • Within the normal band (71% of peer median) for its niche.
Dormant
  • Last raise 5.9 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Hera Testing Laboratories, Inc. is one of 4291 Biotechnology companies tracked from LEXINGTON. By capital raised it ranks in the long tail (ahead of 36% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
9
Investors (latest)
2020-07-30
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2015-02-18 Raised $1.1M (real) Modeled valuation $49M (est)$1.1M$49MSeed2015Seed · 2016-09-12 Raised $700K (real) Modeled valuation $31M (est)$700K$31MSeed2016Seed · 2018-04-10 Raised $525K (real) Modeled valuation $23M (est)$525K$23MSeed2018Seed · 2020-07-30 Raised $1.1M (real) Modeled valuation $45M (est)$1.1M$45MSeed2020+$700K+$525K+$1.1MCumulative $3.4M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.1M · 2015
Seed extension$700K · 2016
Seed extension$525K · 2018
Seed extension$1.1M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$45.4M
Base estimate est.
$769K
Conservative case
$348.3M
Upside case
$5.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $48.8M · 2015-02-182015Seed · modeled $31.1M · 2016-09-12Seed · modeled $23.3M · 2018-04-10Seed · modeled $45.4M · 2020-07-302020
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
5.9 yr
Elapsed time used
5.9 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
22 mo
Avg between rounds
$623K/yr
Capital velocity
11.4 yr
On record since
2015
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.5× of median
This company$3.4M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.6× of median
This company$1.1M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$45.4M
Sector median$64.2M

Raised more than 36% of sector peers (real $). Modeled value above 43% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #126 of 186.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Entac Medical, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Novo Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Korro Bio, Inc. · Seed Raised $4.0M · modeled $177.6M (est)ReGelTec, Inc. · Seed Raised $6.0M · modeled $177.6M (est)TamuroBio Inc. · Seed Raised $4.0M · modeled $177.6M (est)Initial Therapeutics, Inc. · Seed Raised $3.8M · modeled $168.3M (est)Helaina Inc · Seed Raised $4.4M · modeled $164.8M (est)Onchilles Pharma, Inc. · Seed Raised $3.6M · modeled $158.5M (est)UVision 360, Inc. · Seed Raised $4.6M · modeled $155.7M (est)Safeguard Biosystems Holdings Ltd · Seed Raised $3.5M · modeled $155.4M (est)Enable Medicine Inc. · Seed Raised $3.6M · modeled $152.1M (est)Newomics Inc. · Seed Raised $3.9M · modeled $148.7M (est)Hera Testing Laboratories, Inc. (this company) Raised $3.4M · modeled $45.4M (est)Hera Testing Laboratories, Inc.
CompanyStageRaised · realValue · estvs peer med.
Entac Medical, Inc.Seed$4.0M$177.6M2.77×
Novo Biosciences, Inc.Seed$4.0M$177.6M2.77×
Korro Bio, Inc.Seed$4.0M$177.6M2.77×
ReGelTec, Inc.Seed$6.0M$177.6M2.77×
TamuroBio Inc.Seed$4.0M$177.6M2.77×
Initial Therapeutics, Inc.Seed$3.8M$168.3M2.62×
Helaina IncSeed$4.4M$164.8M2.57×
Onchilles Pharma, Inc.Seed$3.6M$158.5M2.47×
UVision 360, Inc.Seed$4.6M$155.7M2.43×
Safeguard Biosystems Holdings LtdSeed$3.5M$155.4M2.42×
Enable Medicine Inc.Seed$3.6M$152.1M2.37×
Newomics Inc.Seed$3.9M$148.7M2.32×
Hera Testing Laboratories, Inc. this companySeed$3.4M$45.4M0.71×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.1M2015-02-18$5.5M$48.8M85%
Seed$700K2016-09-12$3.5M$31.1M85%
Seed$525K2018-04-10$2.6M$23.3M90%
Seed$1.1M2020-07-30$5.3M$45.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.1M2015-02-18
    • First recorded raise — entered as Seed.
    • 15 investors on this round.
  2. Seed$700K2016-09-12
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  3. Seed$525K2018-04-10
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  4. Seed$1.1M2020-07-30
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 9 investors on this round.
Intelligence
2022 ~Q2
Modeled next raise · ~22mo cadence
$2.2M
Modeled next size est.range $1.4M$3.5M
2.0×
Last step-up
$623K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Eric M Ostertag2 other2015-02
Christopher H. Young1 other2020-07
Christopher M Young2016-09
Eric H. Ostertag2020-07
Jack M Crawford2016-09
Michael J. Schlosser2018-04
Thomas M Isett2018-04
Registry & provenance

Hera Testing Laboratories, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1634989
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Vindico NanoBioTechnology, Inc.BiotechnologySeed$1.3M$57.1Mnetwork1 shared operator · same sector · same stage
Nina Biotherapeutics, Inc.BiotechnologySeed$3.4M$39.0Msame sector · same stage
MED DEV CorpBiotechnologySeed$3.3M$42.8Msame sector · same stage
Bergen Medical Products, Inc.BiotechnologySeed$3.3M$39.9Msame sector · same stage
Osteonovus, Inc.BiotechnologySeed$3.6M$47.7Msame sector · same stage
Figure 8 Surgical Inc.BiotechnologySeed$3.6M$55.3Msame sector · same stage
Intuitive Biosciences, Inc.BiotechnologySeed$3.6M$54.3Msame sector · same stage
Thelium Therapeutics Inc.BiotechnologySeed$3.1M$50.7Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Hera Biotech, Inc.BiotechnologySeries A$2.9M92%
Myogenica Inc.BiotechnologyPre-Seed$2.0M88%
Vala Sciences Inc.BiotechnologySeed$88.7M86%
Ora Biomedical, Inc.BiotechnologyPre-Seed$4.4M86%
Cell Microsystems, Inc.BiotechnologySeries A$52.4M85%
BioROSA Technologies IncBiotechnologySeed$8.9M85%
Heligenics, Inc.BiotechnologySeed$11.8M85%
Helaina IncBiotechnologySeed$164.8M85%
Frequently asked
How much funding has Hera Testing Laboratories, Inc. raised?
Hera Testing Laboratories, Inc. has raised approximately $3.4M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Hera Testing Laboratories, Inc.'s estimated valuation?
Provath's modeled valuation for Hera Testing Laboratories, Inc. is approximately $45.4M (modeled range $769K–$348.3M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Hera Testing Laboratories, Inc. at?
Hera Testing Laboratories, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Thu Jul 30.
What does Hera Testing Laboratories, Inc. do and where is it based?
Hera Testing Laboratories, Inc. operates in the Biotechnology sector, based in LEXINGTON.
Explore related

See where Hera Testing Laboratories, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Hera Testing Laboratories, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.